NCT02275338View on ClinicalTrials.gov

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

PHASE2CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

November 9, 2017

Study Completion Date

November 9, 2017

Conditions

Intestinal Obstruction

Interventions

DRUG

Lanreotide Autogel

120mg administered via deep subcutaneous injection at Day 0 and Day 28.

Trial Locations (17)

Unknown

Aalst

Antwerp

Bruges

Ste-Elisabeth Hospital, Brussels

Chimay

Ghent

Haine-Saint-Paul

Libramont

Liège

Mons

Montigny-le-Tilleul

Ostend

Ottignies

Sint-Niklaas

Tournai

Verviers

Yvoir

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ipsen

INDUSTRY